Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Status: Archived
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Status: Archived
Updated: 1/1/1970
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Status: Archived
Scottsdale Healthcare NOAH Clinic
mi
from
Scottsdale, AZ
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Status: Archived
Updated: 1/1/1970
Scottsdale Healthcare NOAH Clinic
mi
from
Scottsdale, AZ
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Status: Archived
Yeshiva University
mi
from
Bronx, NY
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Asthma Disparities in Latino Children:Acculturation,Illness Representations & CAM
Status: Archived
Updated: 1/1/1970
Yeshiva University
mi
from
Bronx, NY
BI671800 in Asthmatic Patients on Inhaled Corticosteroids
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
BI671800 in Asthmatic Patients on Inhaled Corticosteroids
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Denver, CO
BI671800 in Asthmatic Patients on Inhaled Corticosteroids
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)
Status: Archived
1222.29.11004 Boehringer Ingelheim Investigational Site
mi
from
North Dartmouth, MA
BI671800 in Asthmatic Patients on Inhaled Corticosteroids
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)
Status: Archived
Updated: 1/1/1970
1222.29.11004 Boehringer Ingelheim Investigational Site
mi
from
North Dartmouth, MA
BI671800 in Asthmatic Patients on Inhaled Corticosteroids
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Portland, OR
BI671800 in Asthmatic Patients on Inhaled Corticosteroids
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Portland, OR
BI671800 in Asthmatic Patients on Inhaled Corticosteroids
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
BI671800 in Asthmatic Patients on Inhaled Corticosteroids
Randomised, Double Blind, Double Dummy, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 6 Weeks of Oral BI 671800 ED Twice Daily (b.i.d.), Montelukast Once Daily (q.d.) or Placebo in Symptomatic Asthmatic Patients on Low Dose Fluticasone Propionate MDI (Metered Dose Inhaler)
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Bariatric and Obstructive Lung Disease Study II
Effects of Obesity on Airway Caliber and Airway Smooth Muscle Tone
Status: Archived
Johns Hopkins at Greenspring Station Pavilion II
mi
from
Lutherville, MD
Bariatric and Obstructive Lung Disease Study II
Effects of Obesity on Airway Caliber and Airway Smooth Muscle Tone
Status: Archived
Updated: 1/1/1970
Johns Hopkins at Greenspring Station Pavilion II
mi
from
Lutherville, MD
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
GSK Investigational Site
mi
from
Roswell, GA
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Roswell, GA
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
McFarland Clinic, PC
mi
from
Ames, IA
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
McFarland Clinic, PC
mi
from
Ames, IA
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
GSK Investigational Site
mi
from
Weatherford, OK
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Weatherford, OK
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
GSK Investigational Site
mi
from
Klamath Falls, OR
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Klamath Falls, OR
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Clinical Research Facility
mi
from
San Diego, CA
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
San Diego, CA
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Lauderdale, FL
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Clinical Research Facility
mi
from
Asheville, NC
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Asheville, NC
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Clinical Research Facility
mi
from
Bend, OR
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bend, OR
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Clinical Research Facility
mi
from
Anderson, SC
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Anderson, SC
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 µg, 4.5 µg, and 9 µg Delivered Via Symbicort pMDI and Foradil® 12 µg Evaluating the Relative Bronchodilating Effects and Safety in Children
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Rhode Island Hospital
mi
from
Providence, RI
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
Rhode Island Hospital
mi
from
Providence, RI
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Fayetteville, AR
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Fayetteville, AR
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Anaheim, CA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Anaheim, CA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Indianapolis, IN
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Indianapolis, IN
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Westwood, KA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Westwood, KA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Louisville, KY
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Louisville, KY
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Baton Rouge, LA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Baton Rouge, LA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Portland, ME
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Portland, ME
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Grand Rapids, MI
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Grand Rapids, MI
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Georgetown Univ Med Ctr
mi
from
Washington,
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
Georgetown Univ Med Ctr
mi
from
Washington,
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Chesterfield, MO
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Chesterfield, MO
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Grand Island, NE
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Grand Island, NE
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Cherry Hill, NJ
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Cherry Hill, NJ
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Medical University of South Carolina
mi
from
Charleston, SC
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
mi
from
Charleston, SC
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Weatherford, OK
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Weatherford, OK
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Philadelphia, PA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Philadelphia, PA
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Charleston, SC
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Charleston, SC
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Austin, TX
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Austin, TX
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
Burlington, VT
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
Burlington, VT
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
GSK Investigational Site
mi
from
La Crosse, WI
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Four 6-Week Period Cross-Over Study to Evaluate Adding GSK2190915, Montelukast or Placebo Tablets or Salmeterol Inhalation Powder to Fluticasone Propionate Inhalation Powder in Uncontrolled Asthmatic Subjects > or = 12 Years of Age.
Status: Archived
Updated: 1/1/1970
GSK Investigational Site
mi
from
La Crosse, WI
Improving Asthma Outcomes Through Spirometry Distance Learning
Improving Asthma Outcomes Through Spirometry Distance Learning
Status: Archived
Slone Center Office-based Research Network (SCOR) - Boston University
mi
from
Boston, MA
Improving Asthma Outcomes Through Spirometry Distance Learning
Improving Asthma Outcomes Through Spirometry Distance Learning
Status: Archived
Updated: 1/1/1970
Slone Center Office-based Research Network (SCOR) - Boston University
mi
from
Boston, MA
Improving Asthma Outcomes Through Spirometry Distance Learning
Improving Asthma Outcomes Through Spirometry Distance Learning
Status: Archived
Seattle Children's Hospital Research Institute
mi
from
Seattle, WA
Improving Asthma Outcomes Through Spirometry Distance Learning
Improving Asthma Outcomes Through Spirometry Distance Learning
Status: Archived
Updated: 1/1/1970
Seattle Children's Hospital Research Institute
mi
from
Seattle, WA
Improving Asthma Outcomes Through Spirometry Distance Learning
Improving Asthma Outcomes Through Spirometry Distance Learning
Status: Archived
Puget Sound Pediatric Research Network
mi
from
Seattle, WA
Improving Asthma Outcomes Through Spirometry Distance Learning
Improving Asthma Outcomes Through Spirometry Distance Learning
Status: Archived
Updated: 1/1/1970
Puget Sound Pediatric Research Network
mi
from
Seattle, WA
Improving Asthma Outcomes Through Spirometry Distance Learning
Improving Asthma Outcomes Through Spirometry Distance Learning
Status: Archived
University of Washington
mi
from
Seattle, WA
Improving Asthma Outcomes Through Spirometry Distance Learning
Improving Asthma Outcomes Through Spirometry Distance Learning
Status: Archived
Updated: 1/1/1970
University of Washington
mi
from
Seattle, WA
Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Evaluation of Tiotropium 2.5 and 5 Mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 Mcg Twice Daily) in Patient With Moderate Persistent Asthma II
A Phase III Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 and 5 µg Once Daily) Compared With Placebo and Salmeterol HFA MDI (50 µg Twice Daily) Over 24 Weeks in Moderate Persistent Asthma
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA